跳至主要内容
临床试验/2025-525153-39-00
2025-525153-39-00招募中3 期

Effect of vasopressin versus norepinephrine on post-operative mean pulmonary arterial pressure following pulmonary endarterectomy surgery, a randomized open label trial

Fondation Hopital Saint Joseph1 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2026年3月2日最近更新:
干预措施

试验速览

阶段
3 期
状态
招募中
入组人数
90
试验地点
1

研究概览

简要总结

To compare the efficacy of vasopressin versus norepinephrine on the immediate post-operative reduction in mean pulmonary arterial pressure (mPAP) following pulmonary artery endarterectomy.

入排标准

年龄范围
18 years 至 65+ years(18-64 Years, 65+ Years)
接受健康志愿者

入选标准

  • Age ≥18 years;
  • Patient scheduled for pulmonary endarterectomy surgery;
  • In women of childbearing potential: negative serum pregnancy test and use of adequate contraception;
  • Affiliation to the French social care service;
  • Patient able to understand and sign a written informed consent form.

排除标准

  • Emergency surgery;
  • Mesenteric ischemia and/or acute coronary syndrome within the month preceding the intervention;
  • Known allergy to the active substance vasopressin or to any of its excipients;
  • Concomitant coronary bypass procedure or other combined surgery (i.e. valve replacement);
  • mPAP<25 mmHg on preoperative right heart catheterization;
  • Patient participating to another interventional clinical trial;
  • For females only: documented pregnancy or lactation;
  • Patient under tutorship, curatorship or legal protection
  • Patient deprived of liberty.

研究组 & 干预措施

Reverpleg 40 U.I./2 ml solution à diluer pour perfusion

Test

干预措施: Reverpleg 40 U.I./2 ml solution à diluer pour perfusion (Drug)

NORADRENALINE VIATRIS 2 mg/ml SANS SULFITES, solution à diluer pour perfusion

Comparator

干预措施: NORADRENALINE VIATRIS 2 mg/ml SANS SULFITES, solution à diluer pour perfusion (Drug)

研究者

申办方类型
Hospital/Clinic/Other health care facility
责任方
Principal Investigator
主要研究者

Dr. Sylvain DIOP

Scientific

Fondation Hopital Saint Joseph

研究点 (1)

Loading locations...

相似试验